Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Urologia internationalis

• Publication date

  2017-11-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1159/000481438PMID 29161715
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostatectomy Versus Observation for Localized Prostate Cancer: A Meta-Analysis

  2019cited by this paper
• Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

  2017cited by this paper
• The efficacy of acupuncture in managing patients with chronic prostatitis/chronic pelvic pain syndrome: A systemic review and meta‐analysis

  2017cited by this paper
• Physical Activity and Survival After Prostate Cancer.

  2016cited by this paper
• Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.

  2016cited by this paper
• Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer.

  2016cited by this paper
• From obesity to diabetes and cancer: epidemiological links and role of therapies

  2016cited by this paper
• Supplementary Table 1

  2015cited by this paper
• Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.

  2015cited by this paper
• Radiation Therapy after Radical Prostatectomy for Prostate Cancer: Evaluation of Complications and Influence of Radiation Timing on Outcomes in a Large, Population-Based Cohort

  2015cited by this paper
• Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2015cited by this paper
• The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.

  2015cited by this paper
• Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.

  2015cited by this paper
• Relationship between prostate-specific antigen kinetics and detection rate of radiolabelled choline PET/CT in restaging prostate cancer patients: a meta-analysis

  2014cited by this paper
• Radical prostatectomy or watchful waiting in early prostate cancer.

  2014cited by this paper
• Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial.

  2014cited by this paper
• The Optimal Timing to Perform 18F/11C-Choline PET/CT in Patients with Suspicion of Relapse of Prostate Cancer: Trigger PSA versus PSA Velocity and PSA Doubling Time

  2014cited by this paper
• Interval to biochemical recurrence following radical prostatectomy does not affect survival in men with low-risk prostate cancer

  2014cited by this paper
• Detection of Recurrent Prostate Cancer After Radical Prostatectomy : Comparison of 11 C-Choline PET / CT with Pelvic Multiparametric MR Imaging with Endorectal Coil

  2014cited by this paper
• Detection of Recurrent Prostate Cancer After Radical Prostatectomy: Comparison of 11C-Choline PET/CT with Pelvic Multiparametric MR Imaging with Endorectal Coil

  2014cited by this paper
• A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high‐risk features: background and rationale of the Radiotherapy – Adjuvant Versus Early Salvage (RAVES) trial

  2014cited by this paper
• Positive surgical margins after radical prostatectomy: a systematic review and contemporary update.

  2014cited by this paper
• Intermittent versus continuous androgen deprivation therapy.

  2014cited by this paper
• Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.

  2013cited by this paper
• Observation Versus Initial Treatment for Men With Localized, Low-Risk Prostate Cancer

  2013cited by this paper
• Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.

  2013cited by this paper
• Intermittent versus continuous androgen deprivation in prostate cancer.

  2013cited by this paper
• Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes.

  2013cited by this paper
• Radical prostatectomy versus observation for localized prostate cancer.

  2012cited by this paper
• Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.

  2012cited by this paper
• Changes in PSA kinetics predict metastasis‐free survival in men with PSA‐recurrent prostate cancer treated with nonhormonal agents

  2012cited by this paper
• Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.

  2012cited by this paper
• Results from the Scandinavian Prostate Cancer Group Trial Number 4: a randomized controlled trial of radical prostatectomy versus watchful waiting.

  2012cited by this paper
• Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

  2012cited by this paper
• Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy

  2012cited by this paper
• Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients.

  2012cited by this paper
• Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.

  2012cited by this paper
• Imaging techniques for local recurrence of prostate cancer: for whom, why and how?

  2012cited by this paper
• Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy

  2012cited by this paper
• Intermittent androgen suppression for rising PSA level after radiotherapy.

  2012cited by this paper
• The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up

  2012cited by this paper
• Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy.

  2012cited by this paper
• Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

  2012cited by this paper
• Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review

  2012cited by this paper
• High‐intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy

  2011cited by this paper
• Radiotherapy and short-term androgen deprivation for localized prostate cancer.

  2011cited by this paper
• Prostate-specific antigen doubling time predicts the development of distant metastases for patients who fail 3-dimensional conformal radiotherapy or intensity modulated radiation therapy using the Phoenix definition

  2011cited by this paper
• Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.

  2011cited by this paper
• Health‐related quality of life after salvage high‐intensity focused ultrasound (HIFU) treatment for locally radiorecurrent prostate cancer

  2011cited by this paper
• Pathological results and rates of treatment failure in high‐risk prostate cancer patients after radical prostatectomy

  2011cited by this paper
• Salvage radiation in men after prostate‐specific antigen failure and the risk of death

  2011cited by this paper
• Adjuvant radiotherapy following radical prostatectomy for prostate cancer.

  2011cited by this paper
• Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence.

  2011cited by this paper
• Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial

  2010cited by this paper
• External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

  2010cited by this paper
• A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence.

  2010cited by this paper
• Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy

  2010cited by this paper
• Duration of Androgen Suppression in the Treatment of Prostate Cancer

  2010cited by this paper
• Phase III Postoperative Adjuvant Radiotherapy After Radical Prostatectomy Compared With Radical Prostatectomy Alone in pT3 Prostate Cancer With Postoperative Undetectable Prostate-Specific Antigen: ARO 96-02/AUO AP 09/95

  2010cited by this paper
• Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma

  2010cited by this paper
• Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.

  2009cited by this paper
• Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy

  2009cited by this paper
• Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.

  2009cited by this paper
• Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.

  2009cited by this paper
• A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma.

  2009cited by this paper
• Salvage radical prostatectomy for recurrent prostate cancer after radiation therapy

  2009cited by this paper
• Locally recurrent prostate cancer after initial radiation therapy: a comparison of salvage radical prostatectomy versus cryotherapy.

  2009cited by this paper
• Duration of androgen suppression in the treatment of prostate cancer.

  2009cited by this paper
• Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

  2009cited by this paper
• Salvage prostate cryoablation: initial results from the cryo on-line data registry.

  2008cited by this paper
• Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.

  2008cited by this paper
• Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial.

  2008cited by this paper
• Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases.

  2008cited by this paper
• Re: Bianco FJ, Scardino PT, and Eastham JA: Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("Trifecta") (Urology 66(5 suppl): 83-94, 2005).

  2008cited by this paper
• Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy.

  2008cited by this paper
• PSA Doubling Time Predicts for the Development of Distant Metastases for Patients Who Fail 3DCRT Or IMRT Using the Phoenix Definition.

  2008cited by this paper
• Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients

  2007cited by this paper
• Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies.

  2007cited by this paper
• Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10

  2006cited by this paper
• Poorly differentiated prostate cancer treated with radical prostatectomy: long-term outcome and incidence of pathological downgrading.

  2006cited by this paper
• [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].

  2006cited by this paper
• Use of different definitions of biochemical failure after external beam radiotherapy changes conclusions about relative treatment efficacy for localized prostate cancer.

  2006cited by this paper
• Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

  2006cited by this paper
• Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer.

  2006cited by this paper
• Clinical Results of the Prostate HIFU Project

  2006cited by this paper
• Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

  2006cited by this paper
• Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients.

  2005cited by this paper
• Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy.

  2005cited by this paper
• Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

  2005cited by this paper
• Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta").

  2005cited by this paper
• Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography.

  2004cited by this paper
• Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated?

  2004cited by this paper
• Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.

  2004cited by this paper
• Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy.

  2004cited by this paper
• Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up.

  2003cited by this paper
• Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy.

  2003cited by this paper
• Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer.

  2003cited by this paper
• Cancer control with radical prostatectomy alone in 1,000 consecutive patients.

  2002cited by this paper
• Transrectal High-Intensity Focused Ultrasound: Minimally Invasive Therapy of Localized Prostate Cancer

  2000cited by this paper
• Prostate specific antigen only progression of prostate cancer.

  2000cited by this paper

• PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions

  2026influential citation
• ARAMON, a phase 2 open-label trial of darolutamide monotherapy in patients with biochemical recurrence or oligometastatic castration-sensitive prostate cancer after radical prostatectomy or primary radiotherapy.

  2026cites this paper
• Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review

  2025cites this paper
• Long-Term Clinical Outcomes of Radical Prostatectomy Versus Image-Guided and Intensity-Modulated Radiation Therapy for Prostate Cancer: A Retrospective and Comparative Study

  2025influential citation
• Genetic alterations of prostate cancer: in localized and metastatic prostate cancer

  2025influential citation
• Study of predictive factors for response to 177LU-PSMA in patients with metastatic castration-resistant prostate cancer

  2025cites this paper
• Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies

  2025cites this paper
• Research on correlations of miR-374a-5p expression with progression and prognosis of prostate cancer.

  2025cites this paper
• NPRL2 gene expression as a predictor of biochemical recurrence after robot-assisted radical prostatectomy

  2025cites this paper
• Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data.

  2025cites this paper
• Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions

  2025cites this paper
• [18F]PSMA-1007 PET/MR as a Precision Biomarker for Early Detection of Biochemical Recurrence in Prostate Cancer at Very Low PSA Levels

  2025cites this paper
• Prostate-Specific Membrane Antigen (PSMA) PET-CT: Revolutionizing Staging, Restaging, and Treatment Response Assessment

  2025cites this paper
• Preoperative predictors about lymph node metastasis and biochemical recurrence in high-risk prostate cancer patients: a clinic pathological retrospective study

  2025cites this paper
• Does the surgeon’s learning curve impact pentafecta outcomes in radical prostatectomy? a systematic review and meta-analysis

  2025cites this paper
• Comparison of Robot-Assisted, Laparoscopic, and Open Radical Prostatectomy Outcomes: A Systematic Review and Network Meta-Analysis from KSER Update Series

  2025cites this paper
• Recurrence of prostate cancer of rare location: magnetic resonance diagnosis and treatment. Clinical case

  2025cites this paper
• DNA Methylation in Prostate Cancer: Clinical Implications and Potential Applications

  2025cites this paper
• Understanding the upper bound of survival for conducting and critically appraising economic evaluations of low-risk cancers

  2025cites this paper
• Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP)

  2025cites this paper
• Improving the identification of high-risk non-metastatic castration-resistant prostate cancer patients in clinical practice

  2024cites this paper
• FTH1P8 induces and transmits docetaxel resistance by inhibiting ferroptosis in prostate cancer.

  2024cites this paper
• Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models

  2024cites this paper
• An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study

  2024cites this paper
• Salvage Androgen Deprivation Therapy as Potential Treatment for Recurrence after Robot-Assisted Radical Prostatectomy

  2024influential citation
• Patient‐centred pathology reporting improves patient experience and understanding of disease in prostate cancer care

  2024cites this paper
• Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital

  2024cites this paper
• Imaging assessment of prostate cancer recurrence: advances in detection of local and systemic relapse

  2024cites this paper
• Factors Affecting Biochemical Recurrence After Radical Prostatectomy and Validity of CAPRA Score in Predicting Biochemical Recurrence

  2024cites this paper
• Targeting S6K/NFκB/SQSTM1/Polθ signaling to suppress radiation resistance in prostate cancer

  2024cites this paper
• High-Intensity Focus Ultrasound Ablation in Prostate Cancer: A Systematic Review

  2024cites this paper
• Texture Analysis in [18F]-Fluciclovine PET/CT Aids to Detect Prostate Cancer Biochemical Relapse: Report of a Preliminary Experience

  2024cites this paper
• Prognostic Impact and Clinical Implications of Adverse Tumor Grade in Very Favorable Low- and Intermediate-Risk Prostate Cancer Patients Treated with Robot-Assisted Radical Prostatectomy: Experience of a Single Tertiary Referral Center

  2024influential citation
• Revolutionizing of Bioactive Natural Products in Prostate Cancer Research and Care: Promising Discoveries and Future Directions

  2024cites this paper
• Salvage lymphadenectomy or radiation therapy in prostate cancer patients with biochemical recurrence and PET positive lymph nodes after radical prostatectomy: A systematic review and pooled analysis.

  2024cites this paper
• Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retrospective analysis.

  2024cites this paper
• n6-methyladenosine-modified circular RNA family with sequence similarity 126, member A affects cholesterol synthesis and malignant progression of prostate cancer cells by targeting microRNA-505-3p to mediate calnexin

  2024cites this paper
• The Association between Urine N-Glycome and Prognosis after Initial Therapy for Primary Prostate Cancer

  2024cites this paper
• An endoplasmic reticulum stress-related signature featuring ASNS for predicting prognosis and immune landscape in prostate cancer

  2024cites this paper
• Tumor upgrading among very favorable intermediate-risk prostate cancer patients treated with robot-assisted radical prostatectomy: how can it impact the clinical course?

  2024cites this paper
• The impact of prognostic group classification on prostate cancer progression in intermediate-risk patients according to the European Association of Urology system: results in 479 patients treated with robot-assisted radical prostatectomy at a single tertiary referral center

  2024cites this paper
• Is the learning curve of the urology resident for conventional radical prostatectomy similar to that of staff initiating robot-assisted radical prostatectomy?

  2024cites this paper
• Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles.

  2024cites this paper
• Ferroptosis‐Related LncRNA BCRP3 Promotes the Proliferation and Migration of Prostate Cancer

  2024cites this paper
• Salvage cryotherapy for prostate cancer.

  2024influential citation
• PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice

  2024cites this paper
• Effect of 18 F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial

  2023cites this paper
• PSMA PET/CT and PET/MRI in primary staging of prostate cancer and its effect on patient management

  2023cites this paper
• A review of the objective cognitive function measurements in males receiving hormonal therapy for prostate cancer

  2023cites this paper
• Comparison of salvage high dose-rate brachytherapy and external beam radiotherapy for treatment of prostate cancer local recurrence after radical prostatectomy

  2023cites this paper
• Falsch-positive – falsch-negative Befunde – Stellenwert der PSMA-PET/CT beim Staging von Patienten mit Prostatakarzinom

  2023cites this paper
• An MRI assessment of prostate cancer local recurrence using the PI-RR system: diagnostic accuracy, inter-observer reliability among readers with variable experience, and correlation with PSA values

  2023cites this paper
• Endogenous testosterone density associates with predictors of tumor upgrading and disease progression in the low through favorable intermediate prostate cancer risk categories: analysis of risk factors and clinical implications

  2023cites this paper
• Synergizing Data Imputation and Electronic Health Records for Advancing Prostate Cancer Research: Challenges, and Practical Applications

  2023cites this paper
• Manejo de los pacientes con cáncer de próstata localizado y recurrencia bioquímica en España: encuesta médica

  2023cites this paper
• Advanced age is an independent prognostic factor of disease progression in high-risk prostate cancer: results in 180 patients treated with robot-assisted radical prostatectomy and extended pelvic lymph node dissection in a tertiary referral center

  2023cites this paper
• Methylation status of various gene loci in localized prostate cancer: Novel biomarkers for diagnostics and biochemical recurrence.

  2023cites this paper
• Post‐diagnostic metformin and statin use and risk of biochemical recurrence in Veterans diagnosed with prostate cancer

  2023cites this paper
• MR Imaging-Guided Prostate Cancer Therapies.

  2023cites this paper
• Robot-assisted radical prostatectomy following holmium laser enucleation of the prostate: perioperative, functional, and oncological outcomes

  2023cites this paper
• A Five Glutamine-Associated Signature Predicts Prognosis of Prostate Cancer and Links Glutamine Metabolism with Tumor Microenvironment

  2023cites this paper
• Retreatment Plan Success through Patient Health Awareness, Health Behavior, and Access to Doctor after a Focal Therapy Procedure for Prostate Cancer.

  2023cites this paper
• Solitary Abdominal Wall Lymph Node Recurrence in Prostate Cancer Patient with Dramatic Prostate-Specific Antigen Decrease following Metastasectomy

  2023influential citation
• Safety differences across androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.

  2023cites this paper
• Metabolic syndrome-related prognostic index: Predicting biochemical recurrence and differentiating between cold and hot tumors in prostate cancer

  2023cites this paper
• Poorly Controlled Diabetes Mellitus Increases the Risk of Deaths and Castration-Resistance in Locally Advanced Prostate Cancer Patients

  2023cites this paper
• Computed Tomography-Based Radiomics for Long-Term Prognostication of High-Risk Localized Prostate Cancer Patients Received Whole Pelvic Radiotherapy

  2023cites this paper
• Radiomics-Based Inter-Lesion Relation Network to Describe [18F]FMCH PET/CT Imaging Phenotypes in Prostate Cancer

  2023cites this paper
• Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

  2023cites this paper
• Inhibition of orthotopic castration-resistant prostate cancer growth and metastasis in mice by JC VLPs carrying a suicide gene driven by the PSA promoter

  2023cites this paper
• Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.

  2023cites this paper
• Management of patients with localized prostate cancer and biochemical recurrence in Spain: A medical survey.

  2023cites this paper
• Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate Cancer in the United States

  2023influential citation
• The natural history of a delayed detectable PSA after radical prostatectomy

  2023cites this paper
• Development of a ferroptosis-based molecular markers for predicting RFS in prostate cancer patients

  2023cites this paper
• Exosome RNA Sequencing as a Tool in the Search for Cancer Biomarkers

  2022cites this paper
• Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer

  2022influential citation
• PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer

  2022cites this paper
• Management Impact of Metachronous Oligometastatic Disease Identified on 18F-Fluciclovine (Axumin™) PET/CT in Biochemically Recurrent Prostate Cancer

  2022cites this paper
• Focal nodular enhancement on DCE MRI of the prostatectomy bed: radiologic-pathologic correlations and prognostic value

  2022cites this paper
• Emulation of a target trial with sustained treatment strategies: an application to prostate cancer using both inverse probability weighting and the g-formula

  2022cites this paper
• Precision intervention for prostate cancer: Re-evaluating who is at risk.

  2022cites this paper
• Contrast-Enhanced Ultrasound-Magnetic Resonance Imaging Radiomics Based Model for Predicting the Biochemical Recurrence of Prostate Cancer: A Feasibility Study

  2022cites this paper
• Identification and validation of a lipid metabolism gene signature for predicting biochemical recurrence of prostate cancer after radical prostatectomy

  2022cites this paper
• Impact of Clinicopathological Characteristics and Tissue Inhibitor of Metalloproteinase-3 Polymorphism Rs9619311 on Biochemical Recurrence in Taiwanese Patients with Prostate Cancer

  2022cites this paper
• Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: a cohort study with meta-analysis.

  2022cites this paper
• Is there a diagnostic benefit of late-phase abdomino-pelvic PET/CT after urination as part of whole-body 68 Ga-PSMA-11 PET/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy?

  2022cites this paper
• Racial disparities in biochemical recurrence of prostate cancer.

  2022cites this paper
• A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality

  2022cites this paper
• Clinical and Biological Significance of DNA Methylation-Driven Differentially Expressed Genes in Biochemical Recurrence After Radical Prostatectomy

  2022cites this paper
• The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection

  2022cites this paper
• Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients

  2022cites this paper
• Single‐fraction prostate‐specific membrane antigen positron emission tomography‐ and multiparametric magnetic resonance imaging‐guided stereotactic body radiotherapy for prostate cancer local recurrences

  2022cites this paper
• The Tobacco β-Cembrenediol: A Prostate Cancer Recurrence Suppressor Lead and Prospective Scaffold via Modulation of Indoleamine 2,3-Dioxygenase and Tryptophan Dioxygenase

  2022cites this paper
• Current challenges in metastasis research and future innovation for clinical translation

  2022cites this paper
• Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection

  2022cites this paper
• A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality

  2022cites this paper
• Patterns of care for non‐metastatic castration‐resistant prostate cancer: A population‐based study

  2022cites this paper
• A Novel Ferroptosis-Based Molecular Signature Associated with Biochemical Recurrence-Free Survival and Tumor Immune Microenvironment of Prostate Cancer

  2022cites this paper
• Radiomics in prostate cancer: an up-to-date review

  2022cites this paper